on MEDINCELL (EPA:MEDCL)
UZEDY® Achieves $117M in Sales in 2024
Medincell, in partnership with Teva Pharmaceuticals, announced that UZEDY® generated $117 million in sales for 2024, marking its first full year on the market. Fourth-quarter sales reached $43 million, surpassing Teva's updated projection by 17% compared to the $100 million outlook in November 2025.
Teva projects UZEDY® sales of $160 million for 2025, doubling the initial forecast of $80 million for 2024. Medincell benefits from mid to high single-digit royalties and may receive up to $105 million in commercial milestones.
Additionally, the development of the Olanzapine Long-Acting Injectable is progressing. The critical Phase 3 trial's last patient visit is imminent, with a New Drug Application submission anticipated in the second half of 2025.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MEDINCELL news